Company Relief Therapeutics Holding AG Other OTC
Equities
RLFTF
CH0100191136
Biotechnology & Medical Research
Business Summary
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical Products
100.0
%
| 6 | 100.0 % | 6 | 100.0 % | -0.79% |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe (excluding Switzerland)
47.8
%
| 2 | 39.7 % | 3 | 47.8 % | +19.65% |
North America
23.3
%
| 2 | 27.9 % | 1 | 23.3 % | -17.25% |
Rest of the World
22.0
%
| 1 | 19.2 % | 1 | 22.0 % | +13.42% |
Switzerland
6.9
%
| 1 | 13.2 % | 0 | 6.9 % | -48.25% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michelle Lock
CEO | Chief Executive Officer | 55 | 28/22/28 |
Jeremy Meinen
DFI | Director of Finance/CFO | 35 | - |
Ram Selvaraju
CHM | Chairman | 45 | 25/16/25 |
Paolo Galfetti
COO | Chief Operating Officer | 59 | 27/21/27 |
Anthony M. Kim
PRN | Corporate Officer/Principal | - | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ram Selvaraju
CHM | Chairman | 45 | 25/16/25 |
Paolo Galfetti
COO | Chief Operating Officer | 59 | 27/21/27 |
Michelle Lock
CEO | Chief Executive Officer | 55 | 28/22/28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 14,040,837 | 9,248,182 ( 65.87 %) | 1,822,398 ( 12.98 %) | 65.87 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
1,822,398 | 12.98% | 2,630,303 $ |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+20.97% | 46.81B | |
-1.07% | 41.37B | |
+47.41% | 41.29B | |
-6.20% | 28.87B | |
+10.80% | 26.06B | |
-20.68% | 19.13B | |
+32.16% | 12.39B | |
-0.40% | 12.08B | |
+0.03% | 11.96B |